Our London Life Sciences and Health Care team, co-chaired by Matthew Felwick (LAE Partner) and Stephen Bennett (IPMT Partner) will hold this year’s Hogan Lovells Life Sciences Summit on 16 May, from 15h in London. Join us for a series of short sessions to keep you ahead of the latest developments in the industry. The Summit will last for
Imogen Ireland
Hogan Lovells London Life Sciences Summit 2019 – 16 May
2018 – The year the pharma industry felt AI’s impact and potential
Artificial Intelligence (AI) is not new… but this year its impact, and the potential for change, was felt across the pharma industry in areas such as drug discovery, tech collaboration, regulation and patentability. When considering the reasons for this, the answer is not that AI is new. ‘AI’ is an umbrella term covering a spectrum
The skilled machines disrupting drug design
Capable of identifying novel compounds for therapeutic use, AI is saving time and costs in a process that can take around 10 to 15 years and billions of pounds to complete. For the pharmaceutical industry, which has traditionally relied on patents to protect innovation and fund R&D, this should be good news, but is an
EU Patent Office publishes preview of guidelines on patenting AI applications
The preview-version of the EPO’s Guidelines for Examination is out now (link here), and, for the first time ever, there is specific guidance on patenting AI applications – Are there any surprises in the Guidelines? Earlier this year the European Patent Office (“EPO”) held its first ever conference on patenting artificial intelligence (“AI”). Following intensive